Education
About Us
Working with TipRanks
Follow Us
Neuphoria Therapeutics (NEUP)
NASDAQ:NEUP
RESEARCH TOOLSreports
NEUP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.11 - $12.55
Previous CloseN/A
Volume31.57K
Average Volume (3M)28.82K
Market Cap
$14.01M
Enterprise Value-$2.40M
Total Cash (Recent Filing)$17.05M
Total Debt (Recent Filing)AU$172.46K
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Feb 20, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding1,879,962
10 Day Avg. Volume34,790
30 Day Avg. Volume28,825
Financial Highlights & Ratios
PEG Ratio2.48
Price to Book (P/B)69.31
Price to Sales (P/S)0.00
P/FCF Ratio34.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$21.00Price Target Upside181.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Neuphoria Therapeutics News
PremiumCompany Announcements
Neuphoria Therapeutics Delays 10-Q Filing
NEUP FAQ
What was Neuphoria Therapeutics’s price range in the past 12 months?
Neuphoria Therapeutics lowest stock price was $2.11 and its highest was $12.55 in the past 12 months.
What is Neuphoria Therapeutics’s market cap?
Neuphoria Therapeutics’s market cap is $14.01M.
When is Neuphoria Therapeutics’s upcoming earnings report date?
Neuphoria Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is 151 days ago.
How were Neuphoria Therapeutics’s earnings last quarter?
Currently, no data Available
Is Neuphoria Therapeutics overvalued?
According to Wall Street analysts Neuphoria Therapeutics’s price is currently Undervalued.
Does Neuphoria Therapeutics pay dividends?
Neuphoria Therapeutics does not currently pay dividends.
What is Neuphoria Therapeutics’s EPS estimate?
Neuphoria Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neuphoria Therapeutics have?
Neuphoria Therapeutics has 1,879,962 shares outstanding.
What happened to Neuphoria Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Neuphoria Therapeutics?
Currently, no hedge funds are holding shares in NEUP
Company Description
Neuphoria Therapeutics
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.